This site is intended for healthcare professionals

Spectrum Pharmaceuticals announces that the FDA is deferring its action on the BLA for Rolontis to treat neutropenia.

Read time: 1 mins
Last updated:27th Oct 2020
Published:27th Oct 2020
Condition: Neutropenia
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest